OncoMatch/Clinical Trials/NCT06650163
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
Is NCT06650163 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for glioma.
This phase I trial studies how well zirconium (Zr)-89 crefmirlimab berdoxam and immuno-positron emission tomography (PET) identifies areas of immune cell activity in patients with brain tumors that can be removed by surgery (resectable). One important predictor of the immune response is the presence and change in CD8 positive (+) tumor infiltrating lymphocytes (TIL) cells. Identifying the presence and changes in CD8+ cells can be challenging, particularly for participants with central nervous system (CNS) tumors, and usually requires invasive procedures such as repeat tissue biopsies, which may not accurately represent the immune status of the entire tumor. Zr-89 crefmirlimab berdoxam is known as a radioimmunoconjugate which consists of a radiolabeled anti-CD8+ minibody whose uptake can be imaged with PET. Upon administration, Zr 89 crefmirlimab berdoxam specifically targets and binds to the CD8+ cells. This enables PET imaging and may detect CD8+ T-cell distribution and activity and may help determine the patient's response to cancer immunotherapeutic agents more accurately. Giving Zr-89 crefmirlimab berdoxam along with undergoing immuno-PET imaging may work better at identifying immune cell activity in patients with resectable brain tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Tumor Agnostic
Lab requirements
Kidney function
Serum creatinine OR measured or calculated creatinine clearance (GFR can be used in place of creatinine or creatinine clearance) <= 1.5 X institutional ULN OR >= 60mL/min for subjects with creatinine levels > 1.5 X institutional ULN
Liver function
Serum total bilirubin <= 1.5 X institutional ULN OR direct bilirubin <= institutional ULN for subjects with total bilirubin levels > 1.5 institutional ULN; AST and ALT <= 2.5 X institutional ULN OR <= 5 X institutional ULN for subjects with Gilberts syndrome; Albumin >= 2.5 mg/dL
Serum creatinine OR measured or calculated creatinine clearance (GFR can be used in place of creatinine or creatinine clearance) <= 1.5 X institutional ULN OR >= 60mL/min for subjects with creatinine levels > 1.5 X institutional ULN; Serum total bilirubin: <= 1.5 X institutional ULN OR direct bilirubin <= institutional ULN for subjects with total bilirubin levels > 1.5 institutional ULN; AST and ALT <= 2.5 X institutional ULN OR <= 5 X institutional ULN for subjects with Gilberts syndrome; Albumin >= 2.5 mg/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCLA / Jonsson Comprehensive Cancer Center · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify